A team at Biberach University of Applied Sciences and Boehringer Ingelheim systematically compared two CRISPR/Cas9 workflows for generating CHO cell lines lacking nine polysorbate-degrading hydrolases. Polysorbate is a surfactant added to therapeutic protein formulations to prevent aggregation, but host cell-derived hydrolases can enzymatically chop it up, generating free fatty acids that form visible and subvisible particles and compromise drug stability. Removing the offending enzymes has therefore become a promising strategy for stabilizing biologics during manufacturing and storage.

The researchers compared a sequential editing strategy, in which genes were knocked out one or a few at a time over repeated rounds of transfection and single-cell cloning, with a multiplex strategy that removed several targets simultaneously. The sequential lineage required 383 days of cultivation, seven rounds of single-cell cloning, and seven electroporations to reach the final genotype. The multiplex route took only 250 days and four cloning rounds, though it needed eleven electroporations because some guide RNAs worked inefficiently, forcing repeated transfections. Both approaches deleted the same nine hydrolase genes, including lipoprotein lipase, phospholipases, and two large carboxylesterase gene clusters excised with paired guide RNAs spanning 506 and 1,629 kilobases of genomic DNA.

Functionally, both strategies succeeded. A fluorescence-based micelle assay showed that polysorbate retention climbed from roughly 30 to 45 percent in parental controls to more than 75 percent in final knockout clones from either workflow. RNA sequencing confirmed transcript depletion at the targeted loci, and genomic analysis verified editing at every intended site. On paper, the two cell lineages were equivalent. In practice, they were strikingly different organisms.

In fed-batch bioreactor cultures, the sequentially edited clones deteriorated in a stepwise fashion as knockouts accumulated. Peak viable cell density fell from about 25 million cells per milliliter in the parental line to 15 to 17 million in final clones, while harvest viability collapsed from above 90 percent to between 50 and 60 percent. The multiplex clones also declined, but more gently, retaining peak densities of 17 to 21 million cells per milliliter and viabilities between 55 and 80 percent, albeit with greater clone-to-clone variability. Metabolic behavior diverged too: sequential clones showed escalating glucose consumption, reaching 42 to 53 grams per liter by day ten, whereas multiplex clones stayed closer to parental levels at 19 to 27 grams per liter.

Perhaps the most striking physiological change emerged in the sequential lineage after knockout of the Pla2g15 and Lipa genes: cells became larger and carried more DNA, with increased cell diameter correlating with elevated DNA content measured by flow cytometry and with reduced proliferation. This shift was never reversed by subsequent editing steps. Intriguingly, one multiplex clone, M-KO4, independently developed the same enlarged, high-DNA, slow-growing phenotype, suggesting that clone-specific disruptions during repeated manipulation, rather than the knockout targets themselves, drive these undesirable traits.

The transcriptomic data told an even sharper story. Final sequential knockout clones showed 425 upregulated and 415 downregulated genes relative to the parental line, while final multiplex clones displayed a far smaller footprint of 162 up and 109 down. Direct comparison between the two endpoints revealed 894 genes higher and 1,003 genes lower in the sequential clones. On a two-dimensional UMAP projection of global gene expression, sequential intermediates drifted progressively away from the parental state, while the multiplex lineage stayed within a confined transcriptional space. The two workflows ended in largely non-overlapping transcriptomic states despite engineering identical genotypes.

Stage-resolved analysis of when differentially expressed genes first appeared pointed to clonal selection, not the editing events themselves, as the dominant driver. Early sequential intermediates changed only modestly, but the Pla2g15 and Lipa knockout step coincided with a jump of 87 up and 83 down genes, matching the inherited increase in cell size and DNA content. The largest sequential shift, 346 up and 250 down genes, followed deletion of the second carboxylesterase cluster, yet analysis of genes flanking the deleted regions showed no broad local expression changes, arguing against simple position effects. Meanwhile, the multiplex lineage accumulated changes gradually, and even its final step involving seven electroporations produced a shift no larger than several sequential stages. The authors conclude that repeated single-cell isolation and clonal adaptation, consistent with the known genomic plasticity of CHO cells, primarily shape the final cellular state.

The team also probed whether eliminating nine hydrolases triggers compensatory upregulation of alternative polysorbate-degrading enzymes, a key concern for product stability engineering. Across a curated panel of candidate serine hydrolases defined by the conserved catalytic triad associated with active CHO-derived enzymes, most genes showed minimal change. Only Pla1a and Abhd14b rose above threshold in sequential clones, and only Liph in multiplex clones, indicating workflow-specific rather than universal compensation. Notably, Ppt2, a lysosomal thioesterase paralog of the knocked-out Ppt1, was consistently downregulated in both lineages, the opposite of what a simple compensation model would predict.

The practical implications for cell line development are substantial. For non-essential targets such as problematic host cell proteins, the data favor multiplex editing, which reached the same functional endpoint in less time, with fewer cloning rounds, and with less accumulated drift in growth, DNA content, and gene expression. Sequential editing retains value when target biology is uncertain or when individual knockouts might impair essential functions, since intermediate phenotypes can be monitored before proceeding. Either way, the study delivers a sobering message: the engineering process itself, particularly the gauntlet of electroporation, cloning, and selection, can sculpt cellular phenotype and transcriptome as powerfully as the intended genetic modifications, and unfavorable traits acquired early tend to persist through the entire lineage. Choosing an editing strategy, the authors argue, is a critical design parameter in its own right.

Subject of Research: Comparison of sequential versus multiplex CRISPR/Cas9 editing workflows for hydrolase knockout in CHO cells

Article Title: Same hydrolase knockouts, different outcomes: CRISPR/Cas9 editing workflow shapes resulting cellular phenotype and transcriptome in CHO

Article References: Weiß, L., Schneider, S., Otte, K., & Fischer, S. (2026). Same hydrolase knockouts, different outcomes: CRISPR/Cas9 editing workflow shapes resulting cellular phenotype and transcriptome in CHO. Frontiers in Bioengineering and Biotechnology, 14, 1923843. https://doi.org/10.3389/fbioe.2026.1923843

Image Credits: AI Generated

DOI: 10.3389/fbioe.2026.1923843

Keywords: CHO cells, CRISPR/Cas9, gene knockout, polysorbate degradation, hydrolases, cell line development, transcriptomics, multiplex editing, clonal selection, biopharmaceutical manufacturing, RNA-seq, host cell proteins

The biology at stake is subtle. Unlike amino acid sequences, which are encoded in DNA and faithfully translated through RNA, glycosylation is not template-driven. Instead, it emerges from a network of enzymes operating in the endoplasmic reticulum and Golgi apparatus, dependent on nucleotide sugars and cofactors such as manganese, and sensitive to cell stress and nutrient availability. Every therapeutic antibody carries a single heavy-chain glycan at the asparagine 297 residue of its Fc region, typically a complex-type structure whose terminal sugars vary with the culture conditions inside the bioreactor. Medium composition, temperature, dissolved oxygen, pH, feeding strategy, and accumulated waste metabolites all shift the final glycan pattern, which is why batches sometimes fall outside release specifications and why glycosylation remains among the largest manufacturing challenges in the industry.

What makes this challenge paradoxical, according to the perspective, is that the same process sensitivity that plagues manufacturing also represents the most underexploited therapeutic opportunity. Each terminal sugar plays a distinct role in immune engagement. Loss of core fucose increases activating Fc gamma receptor engagement, a strategy already validated in the clinic. Terminal galactose enhances C1q binding and complement-dependent cytotoxicity. Sialic acid is associated with anti-inflammatory activity, although the mechanism remains contested. High-mannose glycoforms are cleared more rapidly from circulation through mannose receptor-mediated uptake and are therefore controlled as a liability. Small changes in the sugar tree can thus translate into meaningful differences in safety, stability, and efficacy.

The clinical precedent is striking. Mogamulizumab became the first FDA-approved biologic produced in a FUT8 knockout cell line in 2018, exploiting the fact that removing core fucose from the Fc glycan increases affinity for the activating receptor Fc gamma RIIIa by more than fifty-fold, thereby enhancing antibody-dependent cellular cytotoxicity by natural killer cells. Obinutuzumab, a type II anti-CD20 antibody approved in 2013, combines afucosylation with a distinct binding mode; in previously untreated patients with chronic lymphocytic leukemia, obinutuzumab plus chlorambucil extended median progression-free survival from 15.2 to 26.7 months compared with rituximab plus chlorambucil. Yet the same Fc gamma RIIIa engagement that drives efficacy also drives cytokine release, and obinutuzumab elicits marked elevations in IL-6 and IL-8 with infusion-related reactions during first infusion. Effector function, the perspective emphasizes, carries an upper as well as a lower bound, meaning glycan control is often defined by proximity to a specified target rather than maximization of a single glycoform.

Sialylation presents a different opportunity with a more uncertain mechanistic foundation. Only a minor fraction of endogenous human antibodies carries terminal alpha 2,6-linked sialic acid, and Chinese hamster ovary cells, the workhorse of antibody manufacturing, lack the ST6GAL1 enzyme needed to install this human-type linkage. Hypersialylated intravenous immunoglobulin has been shown to produce comparable anti-inflammatory efficacy at a fraction of the typical dose, raising the prospect that a recombinantly sialylated monoclonal could recapitulate that benefit at substantially lower cost. However, the originally proposed pathway, in which sialylated Fc engages the lectin receptor DC-SIGN to upregulate the inhibitory receptor Fc gamma RIIB, was derived largely from murine models, and subsequent work in human systems reported no detectable binding of sialylated human IgG to DC-SIGN regardless of glycan composition. The therapeutic hypothesis is supported by functional data but not yet by a settled receptor-level mechanism, a distinction the author argues matters greatly for any developer pursuing a sialylated glyco-better.

On the engineering side, the toolbox has matured considerably. Beyond single-gene knockouts and knock-ins, CRISPR-Cas9 now enables multiplexed disruption of glycosylation pathway genes and site-specific knock-in of heterologous glycosyltransferases at defined genomic loci. One systematic screen of 42 glycosyltransferase genes in CHO cells identified bottlenecks in the N-glycosylation pathway and alleviated them through overexpression, yielding antibody glycan variants with up to 80 percent galactosylated or 70 percent sialylated species, though specific productivity decreased markedly in many overexpressing pools. CRISPR activation of endogenous genes such as MGAT3 and ST6GAL1 has also increased total sialylation. Complementing these genetic approaches, feeding strategies target the substrate side of the same constraint: the Golgi-luminal availability of GDP-fucose, UDP-galactose, and CMP-sialic acid limits glycosyltransferase reaction rates, and targeted feeding of galactose with manganese, the cofactor for galactosyltransferase, has raised antibody galactosylation from roughly 34 to 69 percent. Combining enzyme overexpression with precursor supplementation pushes glycoforms toward their true ceiling, as demonstrated by B4GALT1 overexpression with galactose feeding achieving 82 percent galactosylation without loss of antibody yield.

But engineering the cell line only sets the ceiling; holding the target requires process analytical technology, or PAT, that can monitor glycosylation in near real time. Recent platforms integrate liquid chromatography-mass spectrometry with automated fluidics for protein A purification, deglycosylation, and tryptic digestion, enabling autonomous glycan measurements within a few hours of sample collection. Raman spectroscopy offers a non-invasive alternative that avoids contamination risk, though it relies on partial least squares models that carry risks of poor extrapolation and spectral overlap in complex reactor media. The current limitation, the perspective notes, is a trade-off between slower, more precise methods and rapid approximation methods, and the few-hour latency of LC-MS-based approaches is sufficient for semi-batch processes but problematic for continuous operations running for weeks.

Continuous perfusion bioreactors, which add fresh medium while bleeding off cells to maintain optimal density, represent the prevailing direction in next-generation manufacturing, and a regulatory pathway has developed in parallel. ICH Q13, the harmonized guideline on continuous manufacturing adopted in November 2022 and implemented by the FDA and EMA in 2023, explicitly recognizes PAT-enabled monitoring and real-time release testing as core elements of the control strategy for therapeutic proteins. Single-use continuous facilities achieve approximately 35 percent cost savings relative to stainless-steel batch facilities at annual demand in the hundreds of kilograms, an advantage that narrows at multi-ton scale. Because a glyco-better derives its advantage from enhanced potency that may permit lower dosing, reduced annual mass demand could place such products squarely within the volume range where continuous manufacturing is most economically favorable.

The crux of the argument is that neither cell line engineering nor PAT alone is sufficient; the gap lies in their integration. Glycoengineered cell lines are typically developed and characterized at bench scale with little forethought toward manufacturing-scale performance, and the genetic modifications themselves can alter cellular metabolism in ways that demand a different control strategy than the one designed around the parent line. Conversely, a continuous process designed without a cell line characterized under relevant process stresses leaves the PAT system without a stable biological reference. The result, the author warns, is a glycan specification met probabilistically rather than by rational design. Closed-loop glycosylation control, in which PAT readouts feed directly into automated calculations of how much glycan precursor to feed, would remove the need for operator intervention and substantially increase the probability of maintaining the target glycoform, but four bottlenecks remain: loop dynamics, the absence of a validated interface between analytical instruments and process control systems, the underactuated nature of the available control levers, and the regulatory challenge of qualifying a control system that deliberately varies its actions rather than following a fixed recipe.

The near-term horizon, the perspective concludes, is promising. The first integrated glycan control platforms combining glycoengineered cell lines with perfusion bioreactors operated under at-line, glycan-informed feedback control may emerge in the coming years, enabled by robust rapid analytics interfaces and validated hybrid models of CHO N-glycosylation. The biological knowledge to design monoclonal antibody glyco-betters already exists; the engineering knowledge to manufacture them consistently is converging. Cell line engineering sets the ceiling, the author writes, and the imperative is to develop the process capability that reaches it, together and from the start. While the framework is framed around the IgG1 backbone, where a single conserved glycosylation site per heavy chain keeps the control problem tractable, extending it to Fc-fusion proteins with multiple glycan sites, such as etanercept with its three N-glycosylation sites, would present a considerably harder challenge, making monoclonal antibodies the logical proving ground for this next generation of glycan-intrinsic biomanufacturing.

Subject of Research: Glycan-intrinsic biomanufacturing of monoclonal antibodies through integrated cell line glycoengineering and process analytical technology

Article Title: Glycan-intrinsic monoclonal antibody biomanufacturing

Article References: Gyorgypal, A. (2026). Glycan-intrinsic monoclonal antibody biomanufacturing. Frontiers in Chemical Engineering, 8, Article 1955792. https://doi.org/10.3389/fceng.2026.1955792

Image Credits: AI Generated

DOI: 10.3389/fceng.2026.1955792

Keywords: monoclonal antibodies, N-linked glycosylation, glycoengineering, process analytical technology, continuous biomanufacturing, CHO cells, quality by design, Fc glycan, perfusion bioreactors, CRISPR, ICH Q13, biopharmaceutical manufacturing

The core problem SGE addresses is combinatorial explosion. A synthetic metabolic pathway is not simply a collection of genes; it is a carefully tuned arrangement of coding sequences, promoters, expression levels and subcellular addresses. Each design variable multiplies the number of possible configurations, and in mammalian cells the search space quickly becomes unmanageable. Microbial engineers sidestep this with rapid design-build-test cycles: Escherichia coli doubles every twenty minutes and budding yeast every ninety, so iterative refinement is cheap. Mammalian cells, with doubling times exceeding twenty hours, make such iteration painfully slow. Worse, delivering large DNA constructs into mammalian cells is exponentially less efficient as construct size grows, so brute-force screening of complete multigene pathways has been impractical beyond roughly ten kilobases.

SGE flips the logic of construct design. Instead of building and delivering one large pathway at a time, the researchers assembled a pooled library of small, individually barcoded transcription units, each consisting of a coding sequence paired with a promoter and, in some cases, an organellar localization signal. Because small DNA fragments are vastly easier to synthesize, assemble and package into lentivirus, the library could be delivered at high multiplicity of infection, so each cell received a random assortment of components. Every infected cell thereby became a unique pathway variant, exploring different gene content, stoichiometry and localization simultaneously. After selection for a desired phenotype, sequencing the barcodes from surviving cells reveals which combinations of parts conferred the function.

As a test case, the team targeted branched-chain amino acid biosynthesis. Mammals lost the ability to synthesize nine essential amino acids deep in evolutionary history and must obtain them from food, making amino acid auxotrophy a stringent and convenient selection scheme: cells simply die unless they acquire the pathway. In previous work, the group had shown that four E. coli genes, ilvN, ilvB, ilvC and ilvD, could confer valine prototrophy on CHO cells, but growth remained slow at 3.8 days per doubling, and the same genes failed to enable isoleucine biosynthesis despite overlapping enzymatic steps. For the SGE library, they expanded the toolkit to ten coding sequences, adding ilvA to supply the isoleucine-specific substrate 2-oxobutanoate, two feedback-resistant ilvA variants, and the isozymes ilvG and ilvM, which form an acetohydroxy acid synthase II complex with a strong preference for the isoleucine substrate and insensitivity to end-product inhibition.

Each coding sequence was paired with either the strong EF1a or the medium-strength PGK promoter, with or without a mitochondrial targeting sequence, yielding a forty-member transcription unit library. The researchers infected 2.42 million CHO cells at a multiplicity of infection of 8.8 and used Monte Carlo simulations to confirm that the resulting diversity was sufficient to capture all plausible four- and five-component pathway combinations. After fifteen days of selection in low-valine medium, clonal outgrowths appeared only in the experimental population. All sixteen isolated clones proved valine prototrophic, and the best performers doubled in 1.1 days in valine-free medium, roughly 83 percent of their growth rate in complete medium and a dramatic improvement over the rationally designed pathway of the earlier study.

Barcode sequencing revealed a consistent architectural principle. In strongly prototrophic clones, the winning configuration placed mitochondrially targeted ilvN, ilvB, ilvC and ilvD under PGK promoter control, a solution rational design had never identified. Mitochondrial colocalization of all four genes was enriched forty-eight-fold relative to random expectation, and no clone showed all four enzymes in the cytoplasm. The researchers reconstructed this SGE-informed pathway on a single DNA construct using yeast homologous recombination and Flp-In integration, and it drove valine-free growth at 1.25 days per doubling, substantially outperforming the original design. Isotope tracing with carbon-13-labeled glucose and pyruvate confirmed that the engineered cells were genuinely synthesizing valine endogenously at rates comparable to the native mammalian synthesis of the nonessential amino acid alanine.

The isoleucine results were even more striking. Rational design had failed to produce isoleucine-prototrophic CHO cells, but SGE succeeded. Among forty-six clones selected on low-isoleucine medium, nineteen showed improved prototrophy, and the strongest clone grew in isoleucine-free medium at 1.69 days per doubling. Every strongly prototrophic clone carried barcodes for six genes: ilvB, ilvC, ilvD, ilvG, ilvM and the partially feedback-resistant ilvA(L481F). Again, mitochondrial localization dominated, with the six-gene mitochondrial configuration enriched 217-fold over expectation and the fully cytoplasmic alternative never observed. Mass spectrometry detected the expected carbon-13 isotopologs of isoleucine, confirming endogenous synthesis of a metabolic function last present in the mammalian lineage over 500 million years ago. The integrated constructs spanned roughly 23 to 52 kilobases of synthetic DNA, far beyond what conventional screening approaches can deliver and test.

To demonstrate generality, the team deployed the same lentiviral library in Jurkat cells, a human T lymphocyte line that grows in suspension. Three million infected cells at a lower multiplicity of 3.4 yielded valine-prototrophic clones after selection, with 71 percent of 119 isolated clones passing the prototrophy threshold and the best performers doubling in under about two days without valine. The pathway solution mirrored the CHO result: mitochondrially localized ilvN, ilvB, ilvC and ilvD under PGK control, enriched 283-fold over random expectation. Isoleucine prototrophy, predicted by simulation to be vanishingly rare at the achieved library coverage, did not emerge, illustrating how Monte Carlo modeling of transcription unit distributions and multiplicity can guide experimental design and set realistic expectations before a screen begins.

The datasets generated by SGE also proved rich enough for machine learning. The researchers trained a random forest classifier on the barcode-derived transcription unit composition of each Jurkat clone, using it to predict whether a clone would be prototrophic or auxotrophic. With stratified fourfold cross-validation, the model achieved a mean accuracy of 0.942 and an area under the ROC curve of 0.993, and its top predictive features were precisely the four mitochondrially localized, PGK-driven genes that manual analysis had identified as the optimal pathway. This demonstration points toward a future in which large-scale synthetic perturbation data, rather than observational datasets shaped by natural evolution, train predictive models capable of generative metabolic design in mammalian systems.

The authors acknowledge limitations, including the current reliance on selectable phenotypes, biases introduced during lentiviral packaging that underrepresented certain promoters and coding sequences, and the fact that barcode sequencing reveals integration but not expression, which RNA sequencing must supplement. Even so, the implications are broad. Cells engineered for amino acid prototrophy could reduce the cost and complexity of media for biomanufacturing, cultivated meat and viral vector production, while immune cells metabolically augmented to withstand the nutrient-poor, acidic and inflammatory tumor microenvironment could improve cell therapies for solid cancers. The team anticipates extending SGE to larger libraries, additional essential nutrients, vitamins and growth factors, stress tolerance traits, and integration with CRISPR-based host factor modulation, establishing a scalable framework for pathway-scale engineering of increasingly complex biosynthetic traits in mammalian cells.

Subject of Research: Highly multiplexed mammalian metabolic engineering using barcoded shotgun genetic engineering to screen millions of synthetic amino acid biosynthesis pathways

Article Title: Highly multiplexed mammalian metabolic engineering with a shotgun approach

Article References: Trolle, J., Sessa, S., Wudzinska, A., Grivainis, M., Rincones, K., Rodrick, T., Jones, D. R., Fenyö, D., Pinglay, S., & Boeke, J. D. (2026). Highly multiplexed mammalian metabolic engineering with a shotgun approach. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03318-7

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03318-7

Keywords: shotgun genetic engineering, metabolic engineering, synthetic biology, mammalian cells, CHO cells, Jurkat cells, amino acid biosynthesis, valine, isoleucine, mitochondrial localization, machine learning, high-throughput screening

The work was carried out by Na-Yeong Heo, Mi-Jung Kang, and Yeon-Gu Kim at the Biotherapeutics Translational Research Center of the Korea Research Institute of Bioscience and Biotechnology, with Heo and Kim also affiliated with the KRIBB School of Biotechnology at the Korea University of Science and Technology. Their central insight addresses a long-standing frustration in industrial biomanufacturing: codon optimization has become a routine strategy for boosting recombinant protein expression in mammalian systems, yet improvements in codon-usage-based computational metrics do not always translate into enhanced production performance. In other words, an algorithm that scores a gene as well adapted to a host cell’s codon preferences may still deliver a disappointing yield at the bioreactor scale.

To understand why this matters, it helps to consider the biology of the genetic code. The code is degenerate: most amino acids are specified by multiple three-letter codons, and different organisms favor different synonyms. Since the early days of recombinant DNA technology, scientists have exploited this redundancy, rewriting therapeutic genes to match the codon preferences of the production host in the hope of speeding translation. But codon usage influences far more than translation speed. Synonymous changes can affect mRNA secondary structure, mRNA stability and abundance, the kinetics of translation initiation, co-translational folding of the nascent protein, and even the recruitment of regulatory RNA-binding proteins. Because these effects are intertwined and context-dependent, no single computational metric captures the full picture. That is precisely the gap the Korean team set out to close with an empirical, cell-based approach.

The production host at the heart of the study is the Chinese hamster ovary cell, or CHO cell, the workhorse of the biopharmaceutical industry. CHO cells are used to manufacture a large share of the world’s therapeutic proteins because they can perform complex post-translational modifications—particularly N-linked glycosylation—that are essential for the safety and efficacy of many biologics. Etanercept is a prime example: it is a fusion protein linking the extracellular domain of the human p75 tumor necrosis factor receptor to the Fc portion of human immunoglobulin G1, and it requires proper N-terminal processing and N-linked glycosylation to function correctly. Any engineering strategy that raises yield but compromises these quality attributes would be unacceptable, which is why the researchers built quality assessment directly into their screening pipeline.

Methodologically, the study focused on the 5′ coding region of the etanercept gene, the stretch of DNA immediately downstream of the start codon. This region is known to exert outsized influence on translation initiation and early elongation, making it a strategic target for synonymous redesign. The team constructed a library of synonymous codon variants concentrated in this 5′ region and introduced the variants into Flp-In CHO cells, a specialized line engineered for Flp/FRT-mediated site-specific integration. This system allows an incoming gene to recombine at a defined genomic locus, ensuring that every variant in the library is inserted at the same chromosomal address. The importance of this design choice cannot be overstated: in conventional random integration, each cell clone carries the transgene at a different genomic position, and the resulting position effects—local chromatin environment, enhancer proximity, epigenetic silencing—often swamp any true sequence-dependent differences in expression. By pinning every variant to the same locus, the researchers eliminated this confounding variable and made a fair, apples-to-apples comparison of synonymous sequences possible.

With the library in place, the next challenge was finding the rare high performers among many mediocre ones. The researchers employed a fluorescence-activated cell sorting-based antibody detection assay to enrich variants that produced more etanercept on their cell surfaces or in their secreted product. FACS allows millions of cells to be sorted individually at high speed based on a fluorescent signal proportional to protein production, effectively turning the entire cell population into a searchable library. After enrichment, the top candidates were evaluated under stable gene expression conditions, the gold standard for assessing whether a production advantage is durable rather than a transient artifact of transfection or selection. Three variants emerged from this process as clear winners: ETN-Syn-4, ETN-Syn-14, and ETN-Syn-25.

The productivity gains were striking. Compared with cells carrying the native etanercept sequence, the three top variants yielded 2.08-fold, 2.75-fold, and 2.08-fold higher specific protein productivity, a parameter denoted qp that measures the amount of product generated per cell over time. A nearly threefold improvement in specific productivity is a meaningful advance in an industry where even incremental gains in titer or cell-specific productivity can translate into substantial cost savings across thousands of liters of fermentation capacity. Perhaps the most intriguing finding, however, was what did not change dramatically: the mRNA abundance of the three top-producing variants showed only modest differences from the native sequence. This suggests that the productivity boost was not primarily driven by increased transcription or mRNA stability, pointing instead toward translational mechanisms—more efficient initiation, smoother ribosome transit, or improved co-translational folding—that allow the same amount of messenger RNA to yield more finished protein.

The selected variants also displayed distinct sequence characteristics, differing from one another and from the native gene in their codon-usage profiles. This heterogeneity among the winners is itself informative: it implies there is no single optimal codon recipe, but rather multiple synonymous solutions that converge on high productivity through different combinations of sequence features. Such diversity complicates purely rational design but validates the screening approach, which can discover effective variants that no current algorithm would necessarily rank at the top. The findings reinforce a growing consensus in the field that synonymous codon choice is a rich, underexploited design dimension for bioprocess engineering, one whose effects are best mapped empirically in the actual production host.

Critical to any real-world application is the question of product quality, and here the results were reassuring. The researchers compared etanercept derived from the synonymous variants with native-sequence etanercept across several key quality attributes: N-terminal processing, N-linked glycosylation, size heterogeneity, and binding activity. In each case, the variant-derived protein was comparable to the native product. This means the codon changes boosted quantity without altering the molecular identity or functional integrity of the drug—a crucial distinction, because regulatory agencies demand thorough characterization of glycosylation patterns and other critical quality attributes for every biologic, and even subtle shifts can trigger lengthy revalidation. A silent mutation strategy that preserves product quality while raising yield is therefore far more attractive than approaches that trade quality for quantity.

The broader implications extend well beyond etanercept. The screening framework established in this study—combining site-specific integration, focused synonymous libraries, FACS-based enrichment, and rigorous quality control—offers a generalizable template for optimizing any therapeutic protein produced in CHO cells. As the biopharmaceutical industry faces relentless pressure to reduce manufacturing costs and expand access to biologics, tools that squeeze more product from each cell without new cell lines or process overhauls are increasingly valuable. The work, supported by the National Research Foundation of Korea through the KRIBB Research Initiative Program and by Korea’s Ministry of Trade, Industry and Energy, signals a shift in how codon optimization is practiced: away from purely in silico design and toward empirical, cell-based selection that lets the biology itself reveal which silent spellings speak loudest. For a field built on the assumption that the genetic code’s redundancy is just that—redundant—this study is a reminder that synonymous DNA is anything but silent when it comes to making medicines.

Subject of Research: Empirical screening of synonymous codon variants to enhance therapeutic protein production in Chinese hamster ovary cells

Article Title: Synonymous codon variants identified by in vitro screening enhance etanercept production in CHO cells

Article References: Heo, N.-Y., Kang, M.-J., & Kim, Y.-G. (2026). Synonymous codon variants identified by in vitro screening enhance etanercept production in CHO cells. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14057-9

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14057-9

Keywords: codon optimization, synonymous codon variants, CHO cells, etanercept, Fc-fusion protein, recombinant protein expression, Flp-In site-specific integration, FACS screening, specific productivity, N-linked glycosylation, bioprocess engineering, therapeutic glycoprotein

The core problem the authors confront is combinatorial explosion. Engineering a complex phenotype in a cell typically requires coordinating many genetic changes at once: overexpressing some genes, knocking others down, tuning promoters, and redirecting flux through metabolic networks that span multiple subcellular compartments. Each additional variable multiplies the number of possible designs exponentially. A pathway requiring twenty genetic parts, each with even a handful of candidate variants, generates more combinations than any laboratory could feasibly build and characterize one by one. In bacteria and yeast, researchers have partially sidestepped this wall with pooled libraries and selection, but mammalian cells, with their larger genomes, slower growth, and more elaborate regulation, have lagged behind.

Shotgun genetic engineering borrows the logic of shotgun sequencing and applies it to design. Instead of assembling a complete, specified genetic program and hoping it works, the method introduces a massively diverse pool of genetic variants into a cell population simultaneously. Each cell receives a different random combination of the parts being tested. A carefully chosen selection strategy then acts as the filter: only cells whose particular combination of edits produces the desired biological function survive, proliferate, or emit a measurable signal. Deciphering which combinations the survivors carry effectively reverse-engineers working designs out of the vast design space, without the researchers ever having to guess them in advance.

The authors frame this as a way of making complex phenotypes tractable engineering targets. In their Research Briefing, they note that engineering complex functions into mammalian cells holds profound potential but remains largely intractable, and that SGE’s selection strategies reveal effective designs, facilitating rapid engineering of complex biological functions. The emphasis on selection is crucial. Without a way to distinguish cells that have acquired the desired property from the overwhelming majority that have not, a pool of millions of variants is simply noise. With one, the experiment becomes a search algorithm executed in biological hardware, where evolution-like pressure does the computational heavy lifting.

The study builds on a growing body of work showing that mammalian metabolism can be rewired when the right tools exist. In earlier research, some of the same authors resurrected an essential amino acid biosynthesis pathway in Chinese hamster ovary cells, the workhorse of the biopharmaceutical industry, demonstrating that CHO cells could be engineered to produce valine, an amino acid that mammalian cells normally must import from their environment. That feat, published in eLife in 2022, required solving a multi-gene design problem in a mammalian background and hinted at how valuable a high-throughput search method would be for tackling even more ambitious metabolic programs.

The broader field has been converging on the same conclusion from different directions. A landmark demonstration of metabolic engineering in yeast, published in Nature in 2020, saw researchers reconstruct the biosynthesis of medicinal tropane alkaloids by overexpressing twenty-six genes distributed across six subcellular locations. That achievement showed how intricate multi-compartment engineering could be, but it also underscored the cost: such projects traditionally demand years of iterative, hypothesis-driven tuning. Reviews of cellular metabolism engineering have argued that progress depends on design-build-test-learn cycles, and the bottleneck in mammalian systems has consistently been the scale at which designs can be built and tested.

SGE attacks that bottleneck directly by collapsing the build and test phases into a single pooled experiment. The companion research article, published in Nature Biotechnology by Trolle and colleagues under the title describing highly multiplexed mammalian metabolic engineering with a shotgun approach, provides the experimental demonstration of the concept. Related efforts are pushing in parallel directions: a 2026 Nature paper described a method called CLASSIC for ultra-high-throughput mapping of genetic design space, aimed at optimizing gene circuit designs. Together, these developments suggest that the 2020s are the decade in which mammalian synthetic biology acquires the search-based toolkit that microbial engineering has enjoyed for years.

The implications for biomanufacturing are substantial. CHO cells produce the majority of approved therapeutic proteins, and their metabolism directly determines yield, product quality, and culture robustness. If SGE can routinely identify genetic configurations that improve these traits, it could compress optimization campaigns that once took years into far shorter timelines. Beyond manufacturing, the same logic applies to cell therapies, where engineering immune cells to program complex biological functions, as envisioned in influential reviews of the cell engineering era, requires navigating combinatorial design spaces of receptors, regulators, and metabolic circuits that no rational approach can fully explore.

There are, of course, constraints inherent to the approach that the authors themselves acknowledge through their framing. SGE depends on the existence of a workable selection strategy, which means the desired phenotype must be coupled to survival, growth, or a sortable signal. Phenotypes that are difficult to select for, such as subtle changes in product glycosylation or complex behavioral outputs, will require creative proxy selections or multi-step screening schemes. The method also yields designs that work, but the interpretive step of understanding why they work remains a separate challenge, one that increasingly falls to sequencing, computational modeling, and the growing repertoire of high-throughput genetic mapping techniques.

Even with those caveats, the arrival of a genuinely multiplexed engineering strategy for mammalian cells marks a shift in what is considered feasible. The field has watched metabolic engineering transform yeast into producers of plant-derived medicines and bacteria into chemical factories, while mammalian cell engineering advanced more slowly, one careful modification at a time. By screening millions of combinatorial solutions in a single experiment and letting selection reveal the winners, shotgun genetic engineering promises to bring the exploratory power of pooled library approaches to the most medically and industrially relevant cell types in biology. If the approach generalizes as its proponents hope, the design of mammalian cells with complex, custom-built functions may soon look less like artisanal craft and more like an engineering discipline with search, iteration, and scale at its core.

Subject of Research: High-throughput multiplexed metabolic engineering of mammalian cells using shotgun genetic engineering

Article Title: High-throughput metabolic engineering in mammalian cells

Article References: High-throughput metabolic engineering in mammalian cells. (2026). Nature Biotechnology. https://doi.org/10.1038/s41587-026-03317-8 (Author names are not included in the publisher’s citation export.)

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03317-8

Keywords: metabolic engineering, mammalian cells, shotgun genetic engineering, CHO cells, combinatorial design, genetic engineering, synthetic biology, Nature Biotechnology, selection strategies, biomanufacturing, cell therapy, high-throughput screening

Researchers at University College London, working with scientists at AstraZeneca, report the successful miniaturisation of a semi-perfusion cell screening method from a 24-well microwell plate format down to a 96-well deepwell plate, and then combined it with a multi-parameter ranking tool known as the manufacturability index. The work, led by Marie Dorn with colleagues Christine Ferng, Kerensa Klottrup-Rees, Kenneth Lee and Martina Micheletti, addresses a growing tension in bioprocessing: while manufacturing has been steadily shifting from traditional fed-batch culture toward continuous perfusion, clone screening has remained stubbornly fed-batch, conducted at microlitre or millilitre scale long before perfusion conditions are ever introduced at the bench.

The rationale for closing this gap is grounded in physiology. In fed-batch culture, cells are fed once or a few times and accumulate waste products as nutrients are depleted, so the environment changes dramatically over the run. Perfusion culture, by contrast, continuously exchanges medium while retaining cells, keeping conditions far more stable and allowing much higher cell densities. Because the culture environment shapes cell growth and productivity, clones that look mediocre in fed-batch screening might excel under perfusion—and vice versa. Previous studies have shown that screening under production-representative conditions can alter clone rankings, meaning that conventional fed-batch screens risk discarding clones that would have been the best performers in the actual manufacturing process.

The team had previously validated a semi-perfusion screening method at the 24-well microwell plate scale, demonstrating that operation mode and perfusion rate significantly influence clone performance. But industrial screening pipelines overwhelmingly rely on the smaller 96-well deepwell plate format, which is supported by mature automation hardware, software and user expertise. Adapting semi-perfusion to that format was therefore the logical next step to make production-representative screening compatible with the high-throughput automated workflows that pharmaceutical companies already run. The challenge was that miniaturisation introduces new physical constraints: the team’s shaker platform was limited to a maximum agitation speed of 300 rpm with a 19-millimetre orbital diameter, below the 320 to 350 rpm and larger diameters typically reported for deepwell plate work.

To find workable conditions, the researchers first ran preliminary experiments with a CHO Cobra cell line, testing working volumes between 200 and 400 microlitres. Growth proved feasible at 200 and 300 microlitres, while higher volumes impaired culture performance—likely due to insufficient mixing and oxygen transfer at the limited agitation speed. Encouragingly, cell performance at the validated volumes was comparable to previously published 24-well plate data, giving the team confidence the smaller system could deliver trustworthy results. The final screening protocol used squared 96-well deepwell plates sealed with Duetz sandwich lids to minimise evaporation while preserving gas exchange, with a daily partial medium exchange of 0.75 reactor volumes per day mimicking perfusion with cell retention over a ten-day culture period.

With the platform established, the team screened eight clonally derived Chinese hamster ovary cell lines, all producing the same proprietary monoclonal antibody, at both 200 and 300 microlitre working volumes. Growth dynamics were highly comparable between the two volumes, though a trend toward better sustained growth emerged at 200 microlitres, with cultures at 300 microlitres showing earlier declines in viable cell concentration and viability—consistent with possible inhibitory effects or oxygen limitation at the higher volume. Maximum viable cell concentrations ranged widely, from roughly 5 to 35 million cells per millilitre, revealing substantial natural variation among clones. Space-time yield, a measure of how much product a given culture volume produces per day, peaked between 0.04 and 0.14 grams per litre per day, with a couple of clone-specific anomalies that the authors attribute to analytical variability in HPLC-based protein quantification at very low concentrations.

The heart of the study lies in how the clones were ranked. Traditional selection relies on a single metric—typically cell-specific productivity, the amount of antibody each cell produces per day. When the team ranked the eight clones by this single parameter, the results were sobering. Within the 96-well plate system, rankings were internally consistent across the two working volumes, with clone mAb1_C5 topping both lists and mAb1_C7 consistently last. But when those rankings were compared against the earlier 24-well plate data, only the very best and very worst clones held their positions. Mid-ranked clones shuffled dramatically: mAb1_C4 placed second in both 24-well runs but only fourth or fifth in the deepwell plates, while mAb1_C6 performed far better in the smaller format. In short, single-parameter rankings were robust within a platform but did not travel across scales.

Enter the manufacturability index. Originally developed by Goldrick and colleagues, this metric treats clone selection as a multi-criteria decision-making problem, folding growth, viability, productivity and other indicators into a single composite score in which each parameter is rated against the best and worst performer and weighted according to process priorities. Because the 96-well format’s tiny working volumes limited sampling, the index here used five parameters—maximum viable cell concentration, minimum viability, growth rate, space-time yield and average cell-specific productivity—compared with ten parameters, including five metabolite-related metrics, in the larger 24-well system. Even with the reduced parameter set, the multi-parameter rankings proved markedly more consistent. The same three clones occupied the top three positions at both working volumes, and cross-scale agreement with the 24-well data was stronger than for the single-parameter approach.

Statistical analysis reinforced the story. Spearman rank correlations showed that manufacturability index rankings at 200 microlitres agreed significantly with both 24-well plate runs, with correlation coefficients of 0.714 and 0.690, the latter just missing the conventional significance threshold. Single-parameter rankings, by contrast, reached significance against one 24-well run but not the other, exposing their vulnerability to run-to-run variability. The authors are appropriately cautious: with only eight clones, far fewer than the hundred-plus typical of industrial campaigns, the correlations indicate trends rather than definitive proof. Still, the internal coherence of the results, combined with the clear mechanistic advantage of evaluating clones on multiple fronts, lends weight to the conclusion that richer metrics make early screening more predictive.

The implications reach well beyond one plate format. As biopharmaceutical manufacturing continues its march toward intensified and continuous processes, the ability to screen clones under conditions that genuinely represent production—early, cheaply and at high throughput—becomes a strategic advantage, shortening development timelines and preventing costly late-stage surprises. The authors point toward integrating product quality attributes into the index and harnessing machine learning, multivariate data analysis and automation to push predictive power further. For an industry whose approvals have increased three- to four-fold since 2015, and in which monoclonal antibodies remain the leading class of new therapeutics, choosing the right cell clone on day one may prove one of the highest-leverage decisions in the entire manufacturing chain. This study suggests the industry now has a scalable, data-rich way to make that choice well.

Subject of Research: Miniaturised semi-perfusion screening and multi-parameter manufacturability ranking of CHO cell clones for perfusion biomanufacturing

Article Title: Improved clone selection by combining a manufacturability index with semi-perfusion scale-down screening systems

Article References: Dorn, M., Ferng, C., Klottrup-Rees, K., Lee, K., & Micheletti, M. (2026). Improved clone selection by combining a manufacturability index with semi-perfusion scale-down screening systems. Current Research in Biotechnology, Article 100423. https://doi.org/10.1016/j.crbiot.2026.100423

Image Credits: AI Generated

DOI: 10.1016/j.crbiot.2026.100423

Keywords: CHO cells, clone selection, semi-perfusion, perfusion bioprocessing, manufacturability index, deepwell plates, monoclonal antibodies, cell line development, scale-down models, space-time yield, bioprocess intensification, high-throughput screening

To appreciate why this matters, it helps to understand how the glutamine synthetase system has worked for decades. Chinese hamster ovary cells, or CHO cells, are the workhorses of the biotechnology industry, producing the majority of recombinant therapeutic proteins on the market, from monoclonal antibodies to enzyme replacement therapies. When researchers want a CHO cell line to make a therapeutic protein, they typically link the gene for that protein to the gene for glutamine synthetase, an enzyme that allows cells to synthesize glutamine, an amino acid essential for growth. When the cells are grown in medium lacking glutamine and containing methionine sulfoximine, an inhibitor of glutamine synthetase, only cells that produce enough of the enzyme survive. The logic is straightforward: cells that have integrated more copies of the construct, or that express it more strongly, make more glutamine synthetase and therefore grow better under selection. Over time, this enriches the population for high-producing clones.

But the system has a well-known weakness, and it lies in the intrinsic biochemistry of glutamine synthetase itself. The protein is remarkably stable inside the cell, persisting long after it is made. That stability means that even cells with modest expression of the construct accumulate enough enzyme to survive selection. In practical terms, the selection stringency is low: the survival bar is easy to clear, and cells with suboptimal productivity slip through alongside the rare high performers. Traditional workarounds involve escalating concentrations of methionine sulfoximine or laborious rounds of gene amplification and clone screening, both of which add months to cell line development and introduce regulatory and manufacturing complexities. Methionine sulfoximine, after all, is a chemical inhibitor that must be rigorously controlled and eventually removed from the production process, and amplified gene copies can be unstable over long culture periods.

The Inha team approached the problem from an angle that has become increasingly fashionable in cell engineering: proteostasis, the tightly regulated balance between protein synthesis and protein degradation. Rather than trying to control how much glutamine synthetase mRNA is transcribed or translated, they attacked the protein itself, engineering variants that carry modular degrons, short peptide sequences that tag a protein for destruction by the cell’s own degradation machinery. By fusing these degrons to glutamine synthetase, the researchers created what they call destabilized GS, or dGS, variants that are actively and continuously broken down inside the cell. A cell can only maintain sufficient glutamine synthetase activity if it produces the protein at a very high rate, which in turn requires high expression of the linked construct. The degradation tag effectively raises the survival bar, making selection far more stringent without changing the selection conditions at all.

The researchers tested this concept in CHO cells engineered to express either a reporter protein or Etanercept, a fusion protein that combines an antibody fragment with a tumor necrosis factor receptor and is used to treat autoimmune conditions such as rheumatoid arthritis. When the standard, stable glutamine synthetase was used as the selection marker, the resulting cell pools showed the familiar pattern: a broad distribution of productivity, with many mediocre producers surviving selection. When the destabilized GS variants were used instead, the picture changed markedly. The dGS-selected pools were selectively enriched for cells with markedly enhanced productivity, demonstrating that accelerating protein turnover translates directly into stronger selection pressure. The effect worked across both the reporter system and the commercially relevant Etanercept construct, suggesting the strategy is general rather than product-specific.

Molecular analysis of the enriched pools revealed something particularly interesting about where the productivity gains came from. A common assumption in cell line development is that higher productivity comes from gene amplification, meaning the cells have acquired more copies of the therapeutic gene, often through selection regimes designed to force amplification. But when the team examined the dGS pools, they found that the improvements were driven primarily by increased per-copy mRNA abundance rather than by an increase in gene copy number. In other words, the cells that survived the stringent selection were not those with the most genes, but those that made the most messenger RNA from each copy they had. This distinction is significant for manufacturing, because per-copy expression efficiency can be more stable across long production runs than amplified gene arrays, which are prone to silencing or loss over time.

The performance numbers underscore the practical potential of the approach. The top-performing dGS pool achieved an Etanercept titer of 870 milligrams per liter in shake-flask batch culture, a respectable figure for a non-optimized, drug-free system that did not rely on extensive gene amplification. Equally important, the pool maintained stable production over 80 days of continuous passaging, indicating that the high-producing phenotype was not a transient artifact of selection but a durable property of the enriched cell population. Stability over weeks of culture is a critical requirement for commercial manufacturing, where a production campaign can run for many weeks and any decline in titer translates directly into lost product and higher costs. The fact that these results were obtained without chemical selection agents or amplification regimes suggests the method could simplify both the development timeline and the regulatory dossier for new biologic drugs.

The broader significance of the study lies in its demonstration that proteostasis engineering, the deliberate manipulation of protein degradation rates, can serve as a design tool for selection systems, not just as a way to study protein turnover. By choosing or tuning a degron, researchers can in principle dial in exactly how much of a survival protein a cell must produce to stay alive, converting a binary drug-based selection into a graded, high-stringency filter that favors the best producers. Because the strategy operates at the level of protein stability rather than transcription or translation, it is conceptually orthogonal to existing optimization approaches and could be combined with them. The authors suggest that this capability has the potential to accelerate cell line development and reduce manufacturing complexity in biopharmaceutical production, two goals that the industry pursues relentlessly given the enormous cost and time pressures of bringing a biologic to market.

There are, of course, questions that future work will need to address before degradable selection markers become standard practice in industrial cell line development. The study was conducted at shake-flask scale, and performance in the stirred-tank bioreactors used for commercial manufacturing will need to be confirmed. The long-term behavior of degron-tagged proteins under the metabolic stresses of large-scale culture, and the interaction of accelerated protein degradation with the cellular burden of producing a therapeutic protein at high levels, remain areas for further investigation. Nevertheless, the core result stands as a striking proof of concept: by making an essential enzyme deliberately fragile, the researchers turned the cell’s own protein quality control system into a powerful engine for finding its best producers. In an industry where every percentage point of titer improvement carries real economic weight, teaching selection systems to exploit proteostasis may prove to be one of the more consequential ideas to emerge from cell line engineering in recent years.

Subject of Research: Proteostasis engineering of glutamine synthetase for stringent, drug-free selection of high-producing Chinese hamster ovary cell lines

Article Title: Proteostasis engineering of glutamine synthetase for stringent, drug-free selection in Chinese hamster ovary cells

Article References: Kim, H., Park, J. U., Ha, J., & Baik, J. Y. (2026). Proteostasis engineering of glutamine synthetase for stringent, drug-free selection in Chinese hamster ovary cells. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14015-5

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14015-5

Keywords: CHO cells, glutamine synthetase, proteostasis, degrons, protein degradation, selection stringency, cell line development, biopharmaceutical manufacturing, Etanercept, per-copy mRNA abundance, drug-free selection, protein stability

The research, conducted by a team from DrM Dr. Müller AG and the Zurich University of Applied Sciences, set out to compare cyclical cake filtration against two established approaches: conventional depth filtration and alluvial filtration. Depth filtration, the current industry standard, removes particles by forcing the harvest through a porous bed of filter media in which contaminants are trapped in tortuous channels. It works, but it comes with well-known liabilities. The filter bed gradually clogs as it loads with solids, which means engineers must size filters generously to guarantee that a full batch can be processed before the flow stalls. Oversized filter areas translate directly into higher consumable costs and more waste. Depth filters can also reduce yield through non-specific adsorption, in which product molecules bind to the filter media and are lost before they ever reach the chromatography columns downstream.

Alluvial filtration was developed to ease some of these pressures. In this configuration, a protective layer of diatomaceous earth, a porous sediment derived from fossilized algae, is built up on the filter surface before the harvest is introduced. The diatomaceous earth cake acts as a sacrificial shield, capturing the bulk of the particulate load and protecting the underlying filter media from rapid fouling. This extends the filtration capacity considerably compared with bare depth filtration. Yet even alluvial filtration has limits, and the authors of the new study identified an opportunity to go further by exploiting the same diatomaceous earth chemistry in a fundamentally more dynamic way.

Cyclical cake filtration takes the protective cake concept and turns it into a repeating cycle. Rather than building a single cake and running the batch until it is exhausted, the system forms a diatomaceous earth layer on a filter cloth, processes harvest through it, and then regenerates the cloth for the next cycle. This multi-cycle cloth regeneration is the core innovation. Because the filter medium is repeatedly refreshed during operation, the process can sustain high flow rates for extended periods without the progressive clogging that plagues depth filters. In the experiments reported in the study, cyclical cake filtration maintained higher flow rates than depth filtration and showed no clogging under the conditions tested, a striking result given that clogging is precisely the failure mode that forces manufacturers to oversize their equipment.

Clarification alone is not enough, however. A harvest step must also strip out impurities that would otherwise burden downstream purification. The researchers augmented the cyclical cake filtration process with diatomaceous earth and a range of ion-exchange resins, allowing the filter cake to act not just as a physical sieve but as a chemical polishing stage. With this combination, the filtrate turbidity dropped as low as 2.8 nephelometric turbidity units, an exceptionally clear result for a primary clarification step, while product yields remained between 91 and 94 percent. The process reduced DNA concentrations by up to 95 percent and host cell protein levels by up to 62 percent, figures that approach the performance of conventional two-stage clarification trains. For process developers, that means a single, well-designed filtration operation could potentially simplify or shorten the sequence of steps that normally follows the bioreactor.

Scalability is where many promising lab-scale technologies stumble, and the team addressed this concern directly. They ran filtration studies across three scales, spanning an 18-fold increase in filter area, and found that flow rate behavior and filtrate quality were comparable across the range. Product yield stayed consistent from the smallest to the largest configuration, while impurity levels and turbidity showed only minor variation. This kind of scale-up predictability is essential for biopharmaceutical manufacturers, who must transfer processes from development-scale equipment to commercial facilities with confidence that performance will carry over. A filtration technology whose behavior changes unpredictably with area would introduce exactly the kind of process risk that regulators and manufacturers work hard to eliminate.

The commercial implications become vivid when the numbers are projected to manufacturing scale. For a hypothetical batch of 2,000 liters of CHO culture, the study estimated that cyclical cake filtration would require a primary clarification filter area of just 0.88 square meters. Alluvial filtration, by comparison, would need 16.8 square meters for the same task, and conventional depth filtration would demand 28.5 square meters. The difference is not incremental; it is roughly a 19-fold reduction against alluvial filtration and more than 30-fold against depth filtration. Smaller filter areas mean fewer disposable filter cartridges, less storage space, lower shipping and handling burdens, and a smaller volume of solid waste at the end of each batch. In an industry under growing pressure to reduce both cost of goods and environmental footprint, those are consequential advantages.

To capture the trade-off between speed and footprint in a single figure of merit, the authors combined processing time and filter area into a proposed efficiency parameter. When the three technologies were evaluated through this lens, cyclical cake filtration came out on top. The result highlights a point that is easy to overlook in filtration comparisons: a technology that is fast but requires a huge filter area, or compact but slow, may look attractive on one metric while hiding costs on the other. By folding both dimensions into one parameter, the study offers process engineers a more honest basis for comparing clarification options and for modeling how a change in harvest strategy would ripple through facility design, consumable budgets, and batch scheduling.

The authors are careful to frame cyclical cake filtration as an alternative rather than a wholesale replacement. Depth filtration is deeply embedded in validated manufacturing processes, and any new harvest technology must clear regulatory and operational hurdles before adoption. It is also worth noting that two of the study’s authors are employees of DrM, which manufactures the filtration system evaluated, so the work comes from the technology’s own developers, although the findings are presented in a peer-reviewed, open-access venue with detailed methods that other groups can scrutinize and replicate. Independent confirmation at other sites and with different product molecules will be the natural next step for the field.

Even so, the study lands at a moment when the biomanufacturing industry is actively searching for intensification strategies. Continuous processing, perfusion cultures, and higher-titer fed-batch runs all push more solids through the harvest step, making the limitations of legacy clarification technologies more acute each year. If cyclical cake filtration performs as described at industrial scale, it could allow manufacturers to process harvests faster, with dramatically less filter media, lower waste volumes, and impurity removal that rivals multi-step trains. For an industry in which a single batch of a blockbuster biologic can be worth millions of dollars, a clarification step that protects yield, cuts consumable costs, and shrinks the equipment footprint is not a minor optimization. It is the kind of unglamorous engineering advance that quietly determines how affordable the next generation of antibody therapies can become.

Subject of Research: Cyclical cake filtration for clarification of Chinese hamster ovary cell culture harvests in biomanufacturing

Article Title: Increasing CHO cell harvest efficiency with cyclical cake filtration

Article References: Pynos, C. J.-J., Bucher, T., Mannone, A., Gopalakrishnan, A., & Ott, J. (2026). Increasing CHO cell harvest efficiency with cyclical cake filtration. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14021-7

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14021-7

Keywords: CHO cells, biomanufacturing, cell harvest, clarification, cyclical cake filtration, diatomaceous earth, depth filtration, alluvial filtration, host cell protein, impurity removal, scale-up, process efficiency

The research, carried out by Yongjing Xie and Michael Butler at the National Institute for Bioprocessing Research and Training in Dublin and University College Dublin, tackled a stubborn problem that has plagued hydrolysate users for years. Although hydrolysates are known to boost cell growth and productivity, their molecular composition is extraordinarily complex, and no two production batches are ever quite the same. This batch-to-batch variability has made hydrolysates a risky proposition for manufacturers who must satisfy strict regulatory requirements for consistency. Worse still, the biological mechanisms underlying the beneficial effects of hydrolysates have remained poorly understood, largely because the mixtures contain thousands of molecular species that are difficult to identify individually.

To unravel this complexity, the team combined time-resolved compositional profiling with chemometric analysis, a family of statistical techniques designed to extract meaningful patterns from large, complicated datasets. Culture media were supplemented with different batches of cottonseed hydrolysates and sampled throughout the course of batch cultures lasting ten days. The molecular contents of the samples were mapped using liquid chromatography coupled to high-resolution mass spectrometry, a technique capable of separating and detecting thousands of individual compounds in a single run. Each molecular feature was labelled by its mass-to-charge ratio and retention time, creating a detailed fingerprint of every hydrolysate batch as it evolved over the life of the culture.

The biological results were striking. When CHO DG44 cells, a stably transfected cell line widely used in antibody production, were grown with cottonseed hydrolysate supplementation, the cultures lasted longer and maintained consistently high cell viability throughout the ten-day period. Interestingly, the viable cell density was actually lower than in unsupplemented control cultures, yet antibody productivity was significantly enhanced. This decoupling of cell number from productivity suggests that hydrolysates do not simply feed the cells; they fundamentally change how the cells behave, apparently directing more of their metabolic effort toward making the therapeutic protein rather than merely multiplying.

Metabolic profiling added further depth to the story. Supplementation altered the pattern of nutrient utilization in ways that reduced the accumulation of lactate and ammonia, two metabolic byproducts that are notorious for inhibiting cell growth and degrading product quality in industrial bioreactors. Lower levels of these waste products help explain the extended culture longevity observed in the hydrolysate-supplemented batches. By keeping the cellular environment cleaner, the hydrolysates appear to buy the cells additional productive time, a property that bioprocess engineers prize because longer, healthier cultures translate directly into higher yields from the same equipment.

Perhaps the most consequential finding concerned glycosylation, the process by which sugar chains are attached to antibodies after they are synthesized. Glycosylation is not a cosmetic detail; it governs how long an antibody survives in the bloodstream and how effectively it recruits immune mechanisms. The hydrolysate-based cultures produced antibodies with substantially increased galactosylation, meaning a greater proportion of the attached glycans carried terminal galactose residues. However, the degree of this increase varied between hydrolysate batches, providing the first direct evidence that batch-to-batch compositional differences in the supplement are transmitted all the way through to the quality attributes of the final medicine.

This is where the chemometric analysis proved its worth. By correlating the mass spectrometry fingerprints of each hydrolysate batch with the measured culture outcomes, the researchers identified specific molecular features, tagged by their mass-to-charge ratio and retention time, that tracked with viable cell densities and antibody production. These features now serve as candidate markers, chemical signposts that could eventually allow manufacturers to screen incoming hydrolysate lots before they ever reach a bioreactor. Rather than discovering quality problems after a costly production run fails, companies could one day predict, from a simple analytical profile, whether a given batch will enhance productivity, alter glycosylation, or fall short.

The implications for the biopharmaceutical industry are considerable. Hydrolysates are attractive precisely because they are cost-effective, derived from abundant agricultural byproducts such as cottonseed, and capable of replacing expensive purified media components. But regulatory agencies demand thorough characterization of any substance that touches the production process, and unexplained variability is a liability. By demonstrating a rigorous analytical framework that links chemical composition to biological performance, the Dublin team has effectively provided a template for qualifying hydrolysates with the same analytical rigor applied to the drugs themselves. The approach could accelerate the acceptance of hydrolysate supplements in commercial processes where they have historically been viewed with suspicion.

The study also carries broader scientific weight. It illustrates how modern omics-scale analytical chemistry, paired with multivariate statistics, can crack open systems that were previously treated as black boxes. Protein hydrolysates contain an estimated universe of peptides of varying lengths, free amino acids, vitamins, minerals, and trace organic molecules, and teasing out which components matter has long seemed hopeless. The identification of correlated molecular features does not yet pinpoint the exact bioactive compounds, but it narrows the search dramatically and establishes a causal bridge between what is in the bottle and what comes out of the bioreactor, both in terms of quantity and quality of the antibody product.

For now, the researchers describe their work as providing fundamental insight into how compositional variations of protein hydrolysates relate to CHO cell culture longevity, antibody productivity, and glycosylation. The next steps in the field will likely involve identifying the specific molecules behind the correlated features and testing whether purified versions can reproduce the benefits of the crude hydrolysate. If that succeeds, the industry may gain a new generation of chemically defined supplements that deliver the productivity advantages of hydrolysates without their notorious inconsistency. Until then, the message from this study is clear: every drop of hydrolysate is chemically unique, and that uniqueness matters, right down to the sugar molecules hanging off the medicines that millions of patients depend on. The bioreactors of the future may owe much of their performance to the careful chemical detective work exemplified by this research.

Subject of Research: Compositional variability of cottonseed protein hydrolysates and its impact on CHO cell antibody production and glycosylation

Article Title: Chemometric analysis shows compositional variability in cotton hydrolysates that impacts antibody productivity and glycosylation of CHO cells

Article References: Xie, Y., & Butler, M. (2026). Chemometric analysis shows compositional variability in cotton hydrolysates that impacts antibody productivity and glycosylation of CHO cells. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-13994-9

Image Credits: AI Generated

DOI: 10.1007/s00253-026-13994-9

Keywords: chemometrics, CHO cells, protein hydrolysates, cottonseed hydrolysate, monoclonal antibody, glycosylation, LC-HRMS, cell culture, biopharmaceutical manufacturing, batch variability, metabolism, galactosylation